$ABBV

FDA approves first all-oral combination therapy for untreated chronic lymphocytic leukemia. The fixed-duration treatment showed 35% reduced progression risk versus chemotherapy.

AbbVie declares $1.73 quarterly dividend, maintaining its commitment to shareholder returns. The pharmaceutical company has increased dividends over 330% since 2013.

Alzheimer's therapeutics market projected to exceed $6B by 2026 driven by rising disease prevalence and increased pharma investment in disease-modifying treatments.

Global uterine fibroid treatment market projected to grow 7.63% annually through 2033, reaching $9.43 billion. Growth driven by high disease prevalence and minimally invasive surgical advances.

Global lip augmentation market expected to double from $7.91B (2025) to $17.37B (2035), driven by social media influence, improved technology, and increased mainstream acceptance.

AbbVie stock fell despite strong Q4 results and 10% revenue growth. Investors worry about Humira patent expiration, though new drugs Skyrizi and Rinvoq show promise.

Investors anticipate 2026 market volatility, driving interest in defensive healthcare stocks. AbbVie and Merck offer stable dividends and historical resilience during downturns.